The impact of antimicrobial resistance and aging in VAP outcomes: Experience from a large tertiary care center

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Arvanitis, Marios ^a,b   Anagnostou, Theodora ^a,b   Kourkoumpetis, Themistoklis K ^b   Ziakas, Panayiotis D ^a   Desalermos, Athanasios ^b   Mylonakis, Eleftherios ^a,b  

^a BROWN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ACINETOBACTER; ADULT; AGE; AGED; AGING; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ARTIFICIAL VENTILATION; CANDIDA; CONTROLLED STUDY; ENTEROBACTER; ESCHERICHIA; FEMALE; HAEMOPHILUS; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; KLEBSIELLA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; PSEUDOMONAS; RETROSPECTIVE STUDY; SERRATIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; TERTIARY CARE CENTER; VENTILATOR ASSOCIATED PNEUMONIA;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; PNEUMONIA, VENTILATOR-ASSOCIATED; PROGNOSIS; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS;

EID: 84896345188     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089984     Document Type: Article

References (40)

1. Zimlichman E, Henderson D, Tamir O, Franz C, Song P, et al. (2013) Health Care-Associated Infections: A Meta-analysis of Costs and Financial Impact on the US Health Care System. JAMA Intern Med. doi: 10.1001/jamainternmed.2013.9763
2. Spellberg B, Bartlett JG, Gilbert DN (2013) The future of antibiotics and resistance. N Engl J Med 368: 299-302.
3. Barbier F, Andremont A, Wolff M, Bouadma L (2013) Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 19: 216-228.
4. Bird D, Zambuto A, O'Donnell C, Silva J, Korn C, et al. (2010) Adherence to ventilator-associated pneumonia bundle and incidence of ventilator-associated pneumonia in the surgical intensive care unit. Arch Surg 145: 465-470.
5. Sinuff T, Muscedere J, Cook DJ, Dodek PM, Anderson W, et al. (2013) Implementation of clinical practice guidelines for ventilator-associated pneumonia: a multicenter prospective study. Crit Care Med 41: 15-23.
6. Chung DR, Song JH, Kim SH, Thamlikitkul V, Huang SG, et al. (2011) High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med 184: 1409-1417.
7. Azoulay E, Timsit JF, Tafflet M, de Lassence A, Darmon M, et al. (2006) Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest 129: 110-117. (Pubitemid 43265250)
8. Kourkoumpetis T, Manolakaki D, Velmahos G, Chang Y, Alam HB, et al. (2010) Candida infection and colonization among non-trauma emergency surgery patients. Virulence 1: 359-366.
9. Williamson DR, Albert M, Perreault MM, Delisle MS, Muscedere J, et al. (2011) The relationship between Candida species cultured from the respiratory tract and systemic inflammation in critically ill patients with ventilator-associated pneumonia. Can J Anaesth 58: 275-284.
10. Horan TC, Andrus M, Dudeck MA (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36: 309-332. (Pubitemid 351763841)
11. Hamet M, Pavon A, Dalle F, Pechinot A, Prin S, et al. (2012) Candida spp. airway colonization could promote antibiotic-resistant bacteria selection in patients with suspected ventilator-associated pneumonia. Intensive Care Med 38: 1272-1279.
12. Kanaan AO, Donovan JL, Duchin NP, Field TS, Tjia J, et al. (2013) Adverse Drug Events After Hospital Discharge in Older Adults: Types, Severity, and Involvement of Beers Criteria Medications. J Am Geriatr Soc. doi:10.1111/jgs.12504
13. Cosgrove SE (2006) The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 42 Suppl 2: S82-89.
14. Suk Lee M, Walker V, Chen LF, Sexton DJ, Anderson DJ (2013) The epidemiology of ventilator-associated pneumonia in a network of community hospitals: a prospective multicenter study. Infect Control Hosp Epidemiol 34: 657-662.
15. Hunter JD (2012) Ventilator associated pneumonia. BMJ 344: e3325.
16. Jones RN (2010) Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 51 Suppl 1: S81-87.
17. Michetti CP, Fakhry SM, Ferguson PL, Cook A, Moore FO, et al. (2012) Ventilator-associated pneumonia rates at major trauma centers compared with a national benchmark: a multi-institutional study of the AAST. J Trauma Acute Care Surg 72: 1165-1173.
18. Suka M, Yoshida K, Uno H, Takezawa J (2007) Incidence and outcomes of ventilator-associated pneumonia in Japanese intensive care units: the Japanese nosocomial infection surveillance system. Infect Control Hosp Epidemiol 28: 307-313. (Pubitemid 46480729)
19. Di Pasquale M, Ferrer M, Esperatti M, Crisafulli E, Giunta V, et al. (2013) Assessment of Severity of ICU-Acquired Pneumonia and Association With Etiology. Crit Care Med. doi:10.1097/CCM.0b013e3182a272a2
20. Depuydt PO, Vandijck DM, Bekaert MA, Decruyenaere JM, Blot SI, et al. (2008) Determinants and impact of multidrug antibiotic resistance in pathogens causing ventilator-associated-pneumonia. Crit Care 12: R142.
21. Planquette B, Timsit JF, Misset BY, Schwebel C, Azoulay E, et al. (2013) Pseudomonas aeruginosa ventilator-associated pneumonia. predictive factors of treatment failure. Am J Respir Crit Care Med 188: 69-76.
22. Kaminski C, Timsit JF, Dubois Y, Zahar JR, Garrouste-Orgeas M, et al. (2011) Impact of ureido/carboxypenicillin resistance on the prognosis of ventilator-associated pneumonia due to Pseudomonas aeruginosa. Crit Care 15: R112.
23. Pena C, Gomez-Zorrilla S, Oriol I, Tubau F, Dominguez MA, et al. (2013) Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality. Eur J Clin Microbiol Infect Dis 32: 413-420.
24. Combes A, Luyt CE, Fagon JY, Wollf M, Trouillet JL, et al. (2004) Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am J Respir Crit Care Med 170: 786-792. (Pubitemid 39298995)
25. Parker CM, Kutsogiannis J, Muscedere J, Cook D, Dodek P, et al. (2008) Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. J Crit Care 23: 18-26. (Pubitemid 351400362)
26. Sandiumenge A, Lisboa T, Gomez F, Hernandez P, Canadell L, et al. (2011) Effect of antibiotic diversity on ventilator-associated pneumonia caused by ESKAPE Organisms. Chest 140: 643-651.
27. Tseng CC, Liu SF, Wang CC, Tu ML, Chung YH, et al. (2012) Impact of clinical severity index, infective pathogens, and initial empiric antibiotic use on hospital mortality in patients with ventilator-associated pneumonia. Am J Infect Control 40: 648-652.
28. Beceiro A, Tomas M, Bou G (2013) Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? Clin Microbiol Rev 26: 185-230.
29. Price J, Atkinson S, Llewelyn M, Paul J (2009) Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin Infect Dis 48: 997-998.
30. Otto M (2010) Basis of virulence in community-associated methicillin-resistant Staphylococcus aureus. Annu Rev Microbiol 64: 143-162.
31. American Thoracic Society, Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171: 388-416.
32. Kollef MH (2008) Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis 47 Suppl 1: S3-13.
33. Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, et al. (1998) Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157: 531-539. (Pubitemid 28090546)
34. Martin-Loeches I, Deja M, Koulenti D, Dimopoulos G, Marsh B, et al. (2013) Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Med 39: 672-681.
35. Bouza E, Giannella M, Bunsow E, Torres MV, Granda MJ, et al. (2012) Ventilator-associated pneumonia due to meticillin-resistant Staphylococcus aureus: risk factors and outcome in a large general hospital. J Hosp Infect 80: 150-155.
36. Janssens JP, Krause KH (2004) Pneumonia in the very old. Lancet Infect Dis 4: 112-124.
37. Delisle MS, Williamson DR, Perreault MM, Albert M, Jiang X, et al. (2008) The clinical significance of Candida colonization of respiratory tract secretions in critically ill patients. J Crit Care 23: 11-17. (Pubitemid 351400358)
38. Delisle MS, Williamson DR, Albert M, Perreault MM, Jiang X, et al. (2011) Impact of Candida species on clinical outcomes in patients with suspected ventilator-associated pneumonia. Can Respir J 18: 131-136.
39. Lanspa MJ, Brown SM (2012) Asking the right questions: the relationship between incident ventilator-associated pneumonia and mortality. Crit Care 16: 123.
40. Magill SS, Klompas M, Balk R, Burns SM, Deutschman CS, et al. (2013) Developing a new, national approach to surveillance for ventilator-associated events*. Crit Care Med 41: 2467-2475.